The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in

Lipids videos

BEACON series – Episode 1: Primary prevention of CVD – QRISK® <10%

This interactive BEACON session explores the management of younger patients at high lifetime cardiovascular risk whose QRISK® scores may underestimate their true risk. The faculty will examine how to identify patients who would benefit from earlier intervention, interpret lifetime versus 10-year cardiovascular risk, and optimise lipid-lowering and cardiovascular risk reduction strategies in line with current evidence and guidelines.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

BEACON series – Episode 2: Secondary prevention post-MI and peripheral artery disease

This interactive BEACON session explores the optimisation of secondary cardiovascular prevention in patients with established atherosclerotic cardiovascular disease. Herein, the faculty will examine how to identify and address residual cardiovascular risk, optimise lipid-lowering therapy beyond statins, and implement evidence-based strategies to achieve recommended LDL-C targets.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

BEACON series – Episode 3: CVD risk management in type 2 diabetes

In this interactive BEACON session, the faculty explore the management of cardiovascular risk in people with type 2 diabetes. They examine how to optimise lipid-lowering therapy, blood pressure control and glucose management, alongside addressing renal risk and implementing evidence-based interventions to reduce long-term cardiovascular complications.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

BEACON series – Episode 4: Type 2 diabetes and chronic kidney disease

In this interactive BEACON session, the faculty explore the complexities of managing multifactorial cardiometabolic risk in primary care, looking at the fictional case of a 67-year-old man with long-standing type 2 diabetes, CKD stage 3a with rising albuminuria, obesity and multiple modifiable risk factors.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

“Treatment Limbo” – what is it and how can we avoid it?

Sponsored

Dr Adie Viljoen and Dr Mohamed Elnaggar address the challenge of “Treatment Limbo”, in dyslipidaemia management, where patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets yet remain ineligible for advanced therapies. They introduce a guideline-aligned, alternative approach that tailors treatment to baseline LDL-C and distance to goal, supporting timely intervention and helping to reduce the risk of recurrent cardiovascular events.

Click here to access prescribing information and adverse event reporting information for Praluent® (alirocumab).

MAT-XU-2504094 (v2.0) | August 2026

Masterclass: Looking at lipids – dyslipidemia in CVD prevention

Watch Terry McCormack and Peter Green discuss the national guidelines for primary and secondary prevention of cardiovascular disease (CVD), risk assessment and recommended lipid targets for CVD, and the availability of smart open-access data tools that can reduce health inequalities and improve treatment outcomes for your patients.
QoF indicators for CVD prevention

QOF indicators for CVD prevention

Join Dr Martin Godfrey and Dr Jim Moore as they discuss the topic of cardiovascular management in primary care, highlighting the review of the 2023 Quality and Outcomes Framework (QOF) indicators published by the NHS, cardiovascular disease (CVD) prevention and less-explored areas of therapy.
 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.